Danmörk - danska - SEGES Landbrug & Fødevarer

syngenta nordics a/s - fluazinam - suspensionskoncentrat - 500 g/l fluazinam

Danmörk - danska - SEGES Landbrug & Fødevarer

syngenta nordics a/s - difenoconazol - flydende bejdse - 30 g/l difenoconazol

Danmörk - danska - SEGES Landbrug & Fødevarer

syngenta nordics a/s - thiabendazol, imazalil - flydende bejdse - 250 g/l thiabendazol ; 125 g/l imazalil

Evrópusambandið - danska - EMA (European Medicines Agency)

tetris pharma b.v - glucagon - diabetes mellitus - pancreas hormoner, hormoner glycogenolytic - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

bimeda animal health limited - kobber, kobolt, selen - kontinuert intraruminalt indlæg - 0,3 + 13,4 + 0,5 g

Danmörk - danska - SEGES Landbrug & Fødevarer

dla agro a.m.b.a. - svovl, mangan - flydende middel - 97 g/l svovl ; 166 g/l mangan

Danmörk - danska - SEGES Landbrug & Fødevarer

dansk landbrugs grovvareselskab (dlg) - mangannitrat, mangan - flydende middel - 765,4 g/l mangannitrat ; (~ 235 g/l mangan)

Evrópusambandið - danska - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulin glargin - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus hos voksne, unge og børn i alderen 2 år og derover.

Evrópusambandið - danska - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin glargin - diabetes mellitus - narkotika anvendt i diabetes - behandling af diabetes mellitus i voksne, unge og børn i alderen to år og derover.

Evrópusambandið - danska - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - forløbercellelimfoblastisk leukæmi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.